GSK-4178116A is a live attenuated vaccine commercialized by GSK, with a leading Phase II program in Varicella Zoster (HHV-3) Infections. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of GSK-4178116A’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for GSK-4178116A is expected to reach an annual total of $172 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
GSK-4178116A is under development for the prevention of varicella (chickenpox) caused by the new strain (US) of varicella-zoster virus (VZV). It is administered through subcutaneous route.
GSK is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide. GSK is headquartered in Brentford, Middlesex, the UK.
The company reported revenues of (British Pounds) GBP29,324 million for the fiscal year ended December 2022 (FY2022), an increase of 18.7% over FY2021. The operating profit of the company was GBP6,433 million in FY2022, compared to an operating profit of GBP4,321 million in FY2021. The net profit of the company was GBP14,751 million in FY2022, compared to a net profit of GBP3,874 million in FY2021.
For a complete picture of GSK-4178116A’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.